430 results
Keyword Ipilimumab Remove keyword
-
List item
Human medicine European public assessment report (EPAR): Yervoy
Ipilimumab, Melanoma
Date of authorisation: 12/07/2011, Revision: 33, Authorised, Last updated: 24/08/2020Yervoy, INN-ipilimumab 30 Churchill Place … authorisation) Yervoy ipilimumab On 26 April 2018, the Committee … combination of nivolumab with ipilimumab is established only in patients … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Yervoy, Ipilimumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000117-PIP02-10-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 12/01/2017, Last updated: 20/03/2017, Compliance check: V, 24/02/2017paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M07 … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP02-10-M07 … paediatric investigation plan for ipilimumab (Yervoy), concentrate for … -
List item
Opinion/decision on a Paediatric investigation plan (PIP): Yervoy, Ipilimumab
Decision type: PM: decision on the application for modification of an agreed PIP
Therapeutic area: Oncology
PIP number: EMEA-000117-PIP01-07-M07, Route(s) of administration: Intravenous use, Pharmaceutical form(s): Concentrate for solution for infusion
Decision date: 08/05/2015, Last updated: 15/06/2015, Compliance check: V, 11/12/2015paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07 … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07 … paediatric investigation plan for ipilimumab (Yervoy), (EMEA-000117-PIP01-07-M07 … -
List item
Summary of opinion: Yervoy
ipilimumab, opinion date: 17/09/2020, Positive, Last updated: 18/09/2020ipilimumab … Yervoy Yervoy ipilimumab Ipilimumab … -
List item
Withdrawn application: Yervoy
ipilimumab, date of withdrawal: 30/01/2020, Post-authorisation, Last updated: 23/04/2020Yervoy Yervoy ipilimumab Ipilimumab … -
List item
Human medicine European public assessment report (EPAR): Opdivo
nivolumab, Melanoma, Hodgkin Disease, Carcinoma, Renal Cell, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 19/06/2015, Revision: 32, Authorised, Last updated: 24/08/2020another cancer medicine, ipilimumab, to treat adults whose cancer … used in combination with ipilimumab (another cancer medicine … alone or in combination with ipilimumab. The doctor may need to delay … -
List item
Summary of opinion: Opdivo
nivolumab, opinion date: 17/09/2020, Positive, Last updated: 18/09/2020Opdivo in combination with ipilimumab and 2 cycles of platinum-based … -
List item
Human medicine European public assessment report (EPAR): Keytruda
Pembrolizumab, Melanoma, Hodgkin Disease, Carcinoma, Non-Small-Cell Lung
Date of authorisation: 17/07/2015,
, Revision: 28, Authorised, Last updated: 24/08/2020
Keytruda or another medicine, ipilimumab. Patients treated with Keytruda … compared with 2.8 months with ipilimumab. Also, up to 74% of patients … compared with 59% of patients on ipilimumab. A third study in 1,019 patients … -
List item
Press release: New treatment option recommended for patients with advanced melanoma
CHMP, Last updated: 22/05/2015other comparing Keytruda with ipilimumab, another melanoma treatment … had not previously received ipilimumab and in patients who had previously … had previously received ipilimumab. The Committee also looked …